We performed the analysis of efficacy of ZSP1601 in the 36 study subjects by comparing primary efficacy indicators (ALT, AST, GGT, ALP, and LFC) (Figs. 3–5) and secondary efficacy indicators (Supplementary Table 1) between groups of NAFLD patients. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.